COVID-19: FDA Expands Overseas Inspections Freeze Through April

Industry experts advise companies to prepare for paper-based inspection in light of the US FDA's suspended overseas inspections in response to the COVID-19 crisis.

MT2002_Coronavirus Map_1627847941_1200.jpg

The US Food and Drug Administration has postponed most overseas inspections through April citing federal travel restrictions. One industry expert advises companies to prepare strong documentation in case the FDA begins to remotely conduct paper-based inspections.

On 13 March, the coronavirus crisis reached a new level where President Trump declared it a national emergency allowing national,...

More from Regulation

More from Policy & Regulation

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Warning Letters – June 2025

The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By 

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.